Processa Pharmaceuticals, Inc. (PCSA) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.86

From 52W high−78.61%

Volume3182.00

Market cap$5.18M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.86

From 52W high

−78.61%

Volume

3182.00

Market cap

$5.18M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.4x

P/E (TTM)

—

RSI (14)

55.5

MomentumView details →

1D Return

−4.64%

YTD Return

−34.38%

SummaryUpdated Jun 1, 2026

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) is a clinical-stage biopharmaceutical company founded in 2011 and based in Hanover, Maryland. The company went public in March 2014 and focuses on developing innovative drug products to address unmet medical needs, particularly in oncology and gastrointestinal disorders. Processa operates as a development-stage company with no current revenue, relying on clinical trials to advance its pipeline of potential therapeutic treatments through regulatory approval processes.

Ask drillr about Processa Pharmaceuticals, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

−16.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

4234.62%

ROA (TTM)

−649.33%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+90.50%

FCF YoY

−5.69%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+89.29%

EBITDA YoY

−3.93%

MomentumView details →

1D Return

−4.64%

YTD Return

−34.38%

1Y Return

−78.15%

RSI (14)

55.5

vs 50D SMA

+2.62%

vs 200D SMA

−19.39%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

0.87x

Quick Ratio

0.87x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.19

EPS Surprise

−19.00%

Beats (12Q)

5/12

Next Q EPS Est

−$0.75

Avg Surprise (4Q)

−292.21%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−13.44M

Op. CF (TTM)

−11.97M

Next earningsNov 4, 2026 →

Latest newsMore news →

Processa Pharmaceuticals announced the appointments of Gregory J. Flesher as chief operating officer and Craig Coburn, Ph.D., to leadership positions.2h ago

Processa Pharmaceuticals appointed Sheila Gujrathi, M.D., as Executive Chair of its board of directors.6d ago

Similar companies

AlphaTON Capital Corp.ALP Klotho Neurosciences, Inc.KLTOW Skye Bioscience, Inc.SKYE Niki BioSolutions, Inc.NIKI Instinct Bio Technical Co. Holdings Inc.BIOT Cardio Diagnostics Holdings, Inc.CDIO Find similar companies →

Latest newsMore news →

Processa Pharmaceuticals announced the appointments of Gregory J. Flesher as chief operating officer and Craig Coburn, Ph.D., to leadership positions.2h ago Processa Pharmaceuticals appointed Sheila Gujrathi, M.D., as Executive Chair of its board of directors.6d ago